Gyre Therapeutics Investor Relations Material

Gyre Therapeutics Inc., formerly known as Catalyst Biosciences, Inc., is a biopharmaceutical company engaged in the development and commercialization of therapies for organ fibrosis and inflammatory diseases. The company's main focus is on the development of Hydronidone (F351), a therapeutic aimed at treating Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis), previously known as Nonalcoholic Steatohepatitis (NASH). The company is headquartered in San Diego, California, and its shares are listed on the NASDAQ.